FDA Modifies Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are not eligible for platinum-based chemotherapy.
Article
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are not eligible for platinum-based chemotherapy.